Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo
This study evaluates the safety and effectiveness of PF-02545920 for people with schizophrenia.
Understand this study
What is this study about?
This study evaluates the safety and effectiveness of PF-02545920 for people with schizophrenia.
Who could participate?
Listed age limits: 18 years to 99 years.
- Listed locations
- Glendale and 9 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 35
- Sponsor
- Pfizer
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 99 Years
- Official registry ID
- NCT00570063
- Official title
Show the full official title
A Phase 2, Multicenter, Double-blind, Randomized, Fixed Dose, Parallel Group, 3-week Inpatient Treatment Study To Evaluate The Safety, Efficacy And Pharmacokinetics Of Pf-02545920 Compared With Placebo In The Treatment Of Acute Exacerbation Of Schizophrenia
Recruitment & locations
Glendale · Lemon Grove · Paramount
4 more locations
- San Diego
- New Haven
- Willingboro
- Oklahoma City
Interested in joining this study?
Questions about this study
What is this study about?
This study evaluates the safety and effectiveness of PF-02545920 for people with schizophrenia.
Who is behind this study?
The study sponsor is Pfizer.
Does this study involve medication?
Yes. The study involves medication, including PF-02545920 and Placebo.
Who can participate?
Listed age limits: 18 years to 99 years.
Is this study still recruiting?
The registry lists this study as terminated.
